A simple screening process may enhance monoclonal antibody-based drug development

July 31, 2020

By screening potential monoclonal antibody (mAb)-based drugs solely based on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the drug discovery process, according to a new study. This finding could enable researchers to overcome a major hurdle to drug development by identifying promising mAb-based therapies, which must be administered via injection yet often lack the properties necessary to succeed as solutions. "Therapeutic antibodies that neutralize pathogens are a promising way to treat infectious disease," says Jonathan Kingsbury, the first author of the study. "Selection of well-behaved antibodies with molecular properties that enable streamlined manufacturing, scale-up, and subcutaneous delivery is key for rapid development, particularly during a pandemic response." Although mAbs have emerged as a major class of therapeutic agents, they do not sufficiently enter the bloodstream when taken orally. When these drugs are prepared as solutions so they can be injected, they often exhibit undesirable characteristics such as becoming too viscous or exhibiting a predisposition toward phase separation, precipitation, or aggregation. To determine which factors best predict how mAb-based drug candidates will respond as solutions, Kingsbury and colleagues measured the viscosity and opalescence (a display of milky brightness and colors from light that can serve as an indicator of other inconsistencies) of 59 mAb solutions, including 43 approved products. They correlated these undesirable properties to an array of 23 molecular descriptors to explore whether they were tied to, for example, hydrophobic or colloidal properties. The researchers found that mAb solution behavior could be predicted with greater than 90% accuracy based on solely on its diffusion interaction parameter - a measurement of dynamic light scattering that identifies when the protein will begin to unfold and how this will impact its stability. Since diffusion interaction served as a better predictor than any other attribute Kingsbury et al. tested, they conclude that it may serve as a valuable tool to facilitate mAb-based drug development.

American Association for the Advancement of Science

Related Drug Development Articles from Brightsurf:

FDA support for oncology drug development during COVID-19
This Viewpoint from the U.S. Food and Drug Administration puts into context recent guidance on clinical trials during COVID-19 for oncology and shares insight regarding regulatory challenges and lessons learned.

COVID-19 drug development could benefit from approach used against flu
A new study from researchers at The University of Texas at Austin has found that some antivirals are useful for more than helping sick people get better -- they also can prevent thousands of deaths and hundreds of thousands of virus cases if used in the early stages of infection.

Chemistry breakthrough could speed up drug development
Scientists have successfully developed a new technique to reliably grow crystals of organic soluble molecules from nanoscale droplets, unlocking the potential of accelerated new drug development.

New model of the GI tract could speed drug development
MIT engineers have devised a way to speed new drug development by rapidly testing how well they are absorbed in the small intestine.

Super-charging drug development for COVID-19
Researchers are using cell-free manufacturing to ramp up production of valinomycin, a promising drug that has proven effective in obliterating SARS-CoV in cellular cultures.

Drug development for rare diseases affecting children is increasing
The number of treatments for rare diseases affecting children has increased, a new study suggests.

New opportunity for cancer drug development
After years of research on cell surface receptors called Frizzleds, researchers at Karolinska Institutet in Sweden provide the proof-of-principle that these receptors are druggable by small molecules.

Novel paradigm in drug development
Targeted protein degradation (TPD) is a new paradigm in drug discovery that could lead to the development of new medicines to treat diseases such as cancer more effectively.

Turbo chip for drug development
In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades.

A breakthrough for brain tumor drug development
Glioblastoma is a devastating disease with poor survival stats due in part to a lack of preclinical models for new drug testing.

Read More: Drug Development News and Drug Development Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.